Core Viewpoint - XuanZhu Bio-B (02575) has successfully renewed the inclusion of its innovative drug Annelazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei) in the new National Basic Medical Insurance Drug List (2025) effective from January 1, 2026, following negotiations with the National Healthcare Security Administration [1] Group 1 - Anjiuwei is the first and only domestically developed proton pump inhibitor in China, approved for market launch in June 2023 for the treatment of duodenal ulcers [1] - The drug was first included in the National Basic Medical Insurance Drug List in December 2023, which is expected to stabilize market sales and benefit a larger patient population [1] - The successful renewal of Anjiuwei's inclusion in the 2025 National Basic Medical Insurance Drug List is anticipated to enhance its penetration rate in relevant indications, providing momentum for long-term growth [1]
轩竹生物-B：创新药安久卫 成功续约纳入2025年国家基本医保药品目录